awaiting heart transplantation. The favorable results that were seen in this population led to the design of the multicenter REMATCH (Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart failure) trial.
REMATCH evaluated the efficacy and safety of long-term left ventricular assist device (LVAD) support in patients with chronic end-stage heart failure, compared with patients receiving optimal medical management. Patients were enrolled between May 1998 and July 2001 at 20 transplant centers in the United States. The trial found that 1-year survival rate doubled in the LVAD population, compared with the optimal medical management population. In addition, patients with LVADs had a significant improvement in their quality of life and functional status. 3 Today, the next generation of pumps are in clinical trials, awaiting FDA approval for both bridgeto-transplant (BTT) and destination therapy (DT).
The Utilization of Mechanical Circulatory Support Devices Today
Currently, MCSDs are utilized in 3 realms. The first is BTT. This term indicates that the patient receiving a particular device is a transplant candidate or will be a transplant candidate in the future. It is estimated that at any given time, there are 25 000 patients who could benefit from heart transplantation; however, fewer than 2500 heart transplantations are performed a year. MCSDs have the potential to keep many of these patients alive until a donor heart becomes available.
The second utilization is that of DT or lifelong therapy. This term is used to describe patients who are not transplant candidates and are receiving a MCSD as a lifetime therapy. The pump currently approved by FDA for DT is Heartmate XVE (Thoratec, Pleasanton, Calif).
The third utilization is Bridge-To-Recovery, which indicates that a patient has a potentially recoverable heart. The MCSD is placed to allow the myocardium an opportunity to rest and heal. Patients who have suffered an acute myocardial infarction would be candidates for this therapy. The pumps most widely used in this patient population are ABIOMED BVS 5000 (ABIOMED, Danvers, Mass) and Levitronix CentriMag (Levitronix LLC, Waltham, Mass).
Physiology of Ventricular Assist Device Use
An acute injury of the myocardium or chronic congestive heart failure leads to ineffective emptying of the left ventricle during systole. As the cardiac output decreases, left ventricular end-diastolic pressure will increase. This increase inhibits left atrial filling, causing the pulmonary venous pressure to increase, subsequently causing pulmonary congestion. The pulmonary congestion can, in turn, lead to increased right ventricular end-diastolic pressure. With time, this can result in ineffective emptying of the right ventricle as well. 4 The goal of mechanical circulatory support is to decompress the ventricle, decrease the myocardial workload, and reduce oxygen demand of the myocardium while maintaining adequate systemic perfusion to sustain endorgan function. Use of a VAD will reduce preload, myocardial wall tension, and oxygen consumption. 4 Exercise capacity, as measured by peak oxygen consumption, has been shown to increase significantly 2 months after LVAD implantation. 5
MCSDs Available Today
Because of the large number of devices in clinical use today or under development, the following section will discuss an assortment of pumps.
Total Artificial Hearts
A total artificial heart (TAH) is defined as a blood pump that replaces the explanted native heart in terms of anatomical placement and function. In the past, the TAH was a pneumatic extracorporeal driving system, such as Jarvik 7 (Jarvik Heart, Inc, New York, NY), which today is known as CardioWest (SynCardia Systems, Inc, Tucson, Ariz). These devices were used as BTT devices or as permanent replacement systems.
ABIOMED's AbioCor is the first completely self-contained TAH. Its unique design allows it to be totally implanted within the body. Patients are not tethered to a console or have any tubes exiting their body. AbioCor is intended for use in end-stage heart failure patients whose hearts have irreversible left and right ventricular failure and for whom surgery or medical therapy is not an option. The FDA has given approval for the initial implantations of AbioCor and is currently reviewing the results to determine whether the study should be expanded to include more patients.
Displacement Pumps
These pumps utilize either a pusher plate or compressed air to displace blood back into circulation once the pump is filled with blood. These pumps will generate a pulsatile flow. Because of the air displacement seen with these pumps, there is an audible noise.
Thoratec
Thoratec (Thoratec Corporation, Pleasanton, Calif) VAD is a pneumatic pump that can be used in both adult and pediatric patients. It is approved by FDA as a BTT device, as well as for the temporary support of postcardiotomy patients. Thoratec can support either the right and/or the left ventricle. Patients can be discharged home while on Thoratec, due to the TLC II portable driver. The TLC II driver is the size of a small backpack and weighs approximately 40 lb.
ABIOMED BVS 5000
ABIOMED BVS 5000 is most widely used in patients with potentially recoverable hearts. It is a gravity driven, pneumatic, doublechamber pump that acts similar to the native heart. This pump can support one or both sides of a failing heart. It consists of a separate right-and left-sided pump. Each pump contains an "atrium," a "ventricle," and 2 valves. It is designed for short-term support only, with the typical length of support being 7 to 14 days.
ABIOMED makes an additional displacement pump called the AB 5000. These are paracorporeal (outside the body) pumps that provide temporary support for one or both sides of a failing heart. The system is designed to require a noninvasive procedure when switching a patient from BVS 5000 to AB 5000. This pump is not approved for use for patients discharged from the hospital.
HeartMate XVE
HeartMate XVE is an electrically driven, implantable, pulsatile LVAD. The pump is made of titanium and consists of a blood chamber, a motor chamber, a drive-line, and inflow and outflow conduits. The HeartMate is approved by the FDA as a BTT and DT device. Patients can be discharged home on this device and can maintain a normal lifestyle while at home. This is the only device that does not require patients to be on anticoagulant therapy, other than aspirin.
Novacor LVAD
Novacor (World Heart Inc, Oakland, Calif) LVAD is an implantable, electromechanically driven pump. It has been implanted in more than 1600 patients and is the first MCSD to support a single patient for more than 6 years. It is primarily used as a BTT device. It has both a synchronous mode and a fill-to-empty mode that provides sufficient and variable cardiac output by responding to increased physiological demands. Patients can be discharged home on this device.
Rotary/Continuous Flow/Axial Pumps
Unlike displacement pumps, these pumps generate a continuous flow. Therefore, patients with these pumps often do not have a radial pulse and it is difficult to auscultate a blood pressure, without the use of a Doppler. Automatic blood pressure cuffs will not give an accurate blood pressure reading. These pumps do not generate any outside noise.
HeartMate II
HeartMate II (Thoratec Corporation, Pleasanton, Calif) is an axial flow blood pump that is presently in the pivotal stage of its trial. It is 80% smaller than HeartMate XVE and has a flow capacity of 3 to 10 L/min. To date, it has been implanted in more than 200 patients in the United States and Europe. This device is indicated for patients waiting for a heart transplant as well as DT.
MicroMed DeBakey
DeBakey (MicroMed Technology, Inc, Houston, Tex) is an implantable, miniaturized, axial continuous flow LVAD capable of supporting the left ventricle with up to 10 L of flow per minute. Its smaller size allows patients with a smaller body type to be implanted with the device. Two Phase III pivotal clinical trials are presently being conducted in the united States, one for BTT and one for DT. In March of 2006, MicroMed announced the initiation of a multicenter evaluation of its newest design of the DeBakey VAD. The new pump design is approximately the size of a "C" cell battery and weighs only 4 oz.
Jarvik 2000 FlowMaker
Jarvik 2000 FlowMaker (Jarvik Heart, Inc, New York, NY) is an axial flow pump that measures 25 mm in diameter by 55 mm in length. It is an intraventricular pump; therefore, there is no pump pocket or inflow cannula. It can be implanted using a sternotomy, thoracotomy, or subcoastal approach. The controller is all analog and runs the pump at speed settings of 8000 to 12 000 RPMs. Each of the system's 2.5 lb batteries will last for up to 8 hours. There have been 133 implants to date, with the longest period of survival being 5.7 years in a patient on permanent support.
Impella
The Impella recovery (ABIOMED, Danvers, Mass) is a biventricular intracardiac pump that can support a patient for up to 7 days. Only 6.4 mm in diameter, this first recovery system for cardiac surgery pumps up to 4.5 L of blood per minute. The system has been in clinical use since January 2002 and has been used in more than 200 cases.
The Impella acute (ABIOMED, Danvers, Mass) pump has a diameter of 4 mm. Because of its small dimensions, it can be inserted via lower limb arteries and veins. It has been tested in more than 40 clinical trials and is now Conformite Europeene certified for clinical use in Europe.
Berlin Heart Incor LVAD
Incor (Berlin Heart Inc, Northborough, Mass) is an electrically powered, axial pump. This pump is unique in that the pump impeller is suspended by wear-free magnetic bearings.
TandemHeart Percutaneous VAD
TandemHeart (Cardiac Assist Inc, Pittsburgh, PA) percutaneous VAD is a continuous flow centrifugal pump that is placed outside of the body. It can be inserted either by a cardiovascular surgeon in the operating room or by cardiologists in cardiac catheterization lab. Cannulas are inserted percutaneously through the femoral vein and advanced across the intraarterial septum into the left atrium. It has been used in postcardiotomy cardiogenic shock patients and as a bridge to a longer term pump. TandemHeart provides shortterm support from a few hours up to 14 days.
VentrAssist LVAD
VentrAssist (Ventracor Inc., Glendale, Colo) is an LVAD that is utilized for both BTT and DT. It has only one moving part, a hydrodynamically suspended impeller. It is designed to have no wearing parts and cause no hemolysis of blood cells. Its small size makes it suitable for both adults and children. This device is currently under clinical trial in the United States.
Magnetically Levitated Pumps Levitronix CentriMag
Levitronix CentriMag is a continuous flow, centrifugal-type rotary blood pump that is placed outside of the body. The only moving component within the pump is the impeller, which is magnetically levitated and rotated in a contact-free manner. The pump can rotate at speeds of 1500 rpm to 5500 rpm and can provide flows up to 9.9 L/min. Compared with other devices, Levitronix CentriMag is unique in that it is designed to operate without mechanical bearings or seals. In the United States, Levitronix CentriMag remains under investigation for use as a short-term device that would provide support for up to 14 days for patients with postcardiotomy cardiogenic shock, or acute ischemic cardiomyopathy.
Pediatric Circulatory Support
Mechanical circulatory support with extracorporeal membrane oxygenation (ECMO) or VADs has increasingly become an important tool for the treatment of infants and children with congenital and acquired cardiovascular disease who experience cardiopulmonary failure and circulatory collapse. There are 30 000 new cases of congenital heart disease diagnosed each year, with an annual mortality rate of 5000 to 6000. 6 At least 20% of these deaths are related to ventricular failure, and these patients would be candidates for ventricular assist devices. 6 Most clinical experience to date has involved the short-term support of patients weighing 6 kg and above. 7 Currently, ECMO remains the most commonly used form of MCSD for these patients.
There are several pulsatile and continuous flow devices in existence that have been utilized successfully for both short-and midterm pediatric support. These include DeBakey VAD Child, Berlin Heart Excor, Medtronic Biomedicus Pump, and ABIOMED BVS 5000. DeBakey VAD Child (MicroMed Technology, Inc, Houston, Tex) is the only approved miniaturized implantable VAD in the United States available for children. It has been approved by the FDA under the Humanitarian Device Exemption Program. It is designed to support the left ventricle in children aged 5 to 16 years who are awaiting heart transplantation. EXCOR Pediatric (Berlin Heart, Inc, Northborough, Mass) has specifically been developed for use in infants and toddlers. It offers blood pumps of 10 mL, 25 mL, 30 mL, 50 mL, and 60 mL volume.
The VADs of the Future
The goal for the VADs of the future is to be utilized as a long-term therapy, lasting for up to 10 to 15 years. This is likely not feasible with the current technology's mechanical, blood-immersed slide bearings. Therefore, several leading assist device companies are working on designing pumps with magnetically levitated rotors. One such pump is HeartMate III (Thoratec Corporation, Pleasanton, Calif).
Future VADs will be driveline free, therefore eliminating the incidence of driveline site infections. This will be achieved through the integration of transcutaneous energy transmission systems, which will allow the pump to be completely implantable. Pumps will become increasingly smaller, allowing for a wider population that can be implanted and providing for an increased ease of implant.
The technology of MCSDs has given the gift of life to many who have lost quality of life and the capacity to live because of the ravages of heart failure. The future of this therapy will continue to grow and improve as complementing technology in batteries and cell therapy develop.
